Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the operating margin high or low?
The operating margin of -271.90% is in line with its 5-year average of -294.91%, near the high end of its 5-year range (-7137.00%–85.85%).
63.49% above its 12-month average of -744.80%.
Reported quarterly operating margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2182.78%.
OPERATING MARGIN
-271.90%
OPERATING MARGIN AVG TTM
-744.80%
OPERATING MARGIN AVG 3Y
-372.76%
OPERATING MARGIN AVG 5Y
-294.91%
OPERATING MARGIN AVG 10Y
N/A
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+63.49%
CURRENT VS 3Y AVG
+27.06%
CURRENT VS 5Y AVG
+7.80%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 553 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
Opus Genetics, Inc.
Market Cap
$363.29M
Operating Margin
-271.90%
TTM Avg
-744.80%
3Y Avg
-372.76%
5Y Avg
-294.91%
Market Cap
$362.03M
Operating Margin
-14.22%
TTM Avg
-4.51%
3Y Avg
-387.94%
5Y Avg
-2012.06%
Market Cap
$360.14M
Operating Margin
-130.65%
TTM Avg
-155.28%
3Y Avg
-156.88%
5Y Avg
-129.07%
Market Cap
$353.59M
Operating Margin
24.85%
TTM Avg
23.00%
3Y Avg
24.99%
5Y Avg
31.17%
Market Cap
$348.55M
Operating Margin
-18.00%
TTM Avg
-67.22%
3Y Avg
-104.89%
5Y Avg
-90.63%
Market Cap
$373.86M
Operating Margin
-31.98%
TTM Avg
-34.62%
3Y Avg
-233.89%
5Y Avg
-229.53%
Market Cap
$341.28M
Operating Margin
-65.36%
TTM Avg
-64.13%
3Y Avg
-75.36%
5Y Avg
-72.00%
Market Cap
$341.50M
Operating Margin
0.00%
TTM Avg
-13402.79%
3Y Avg
-7027.62%
5Y Avg
-5128.57%
Market Cap
$380.58M
Operating Margin
0.00%
TTM Avg
0.00%
3Y Avg
-104.57%
5Y Avg
-176.82%
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Opus Genetics, Inc. (IRD) | $363.29M | -271.90% | -744.80% | -372.76% | -294.91% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $362.03M | -14.22% | -4.51% | -387.94% | -2012.06% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $360.14M | -130.65% | -155.28% | -156.88% | -129.07% |
| Embecta Corp. (EMBC)vs › | $353.59M | 24.85% | 23.00% | 24.99% | 31.17% |
| Agenus Inc. (AGEN)vs › | $348.55M | -18.00% | -67.22% | -104.89% | -90.63% |
| Canopy Growth Corporation (CGC)vs › | $373.86M | -31.98% | -34.62% | -233.89% | -229.53% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $341.28M | -65.36% | -64.13% | -75.36% | -72.00% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $341.50M | 0.00% | -13402.79% | -7027.62% | -5128.57% |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $380.58M | 0.00% | 0.00% | -104.57% | -176.82% |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
99.9%
Operating Margin
-271.9%
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | OPERATING MARGIN |
|---|---|
| 2026-06-30 | -2182.78% |
| 2026-03-31 | -665.92% |
| 2025-12-31 | -296.33% |
| 2025-09-30 | -269.93% |
| 2025-06-30 | -309.02% |
| 2025-03-31 | -227.21% |
| 2024-12-31 | -883.98% |
| 2024-09-30 | -207.11% |
| 2024-06-30 | -748.92% |
| 2024-03-31 | -450.50% |
| 2023-12-31 | -321.05% |
| 2023-09-30 | 53.51% |
| 2023-06-30 | -146.68% |
| 2023-03-31 | -350.54% |
| 2022-12-31 | 85.85% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | -865.44% |
| 2021-06-30 | -7137.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
